Predicting osimertinib‐treatment outcomes through <i>EGFR</i> mutant‐fraction monitoring in the circulating tumor DNA of <i>EGFR</i> T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)
Molecular oncology